Cargando…

The Response of Variant Histology Bladder Cancer to Intravesical Immunotherapy Compared to Conventional Cancer

BACKGROUND: High-grade urothelial carcinomas (UCs) often show foci of variant differentiation. There is limited information in the literature about the response of these variant urothelial tumors to immunotherapy with bacillus Calmette–Guerin (BCG). We compared the response, to treatment with BCG, o...

Descripción completa

Detalles Bibliográficos
Autores principales: Gofrit, Ofer N., Yutkin, Vladimir, Shapiro, Amos, Pizov, Galina, Zorn, Kevin C., Hidas, Guy, Gielchinsky, Ilan, Duvdevani, Mordechai, Landau, Ezekiel H., Pode, Dov
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4791377/
https://www.ncbi.nlm.nih.gov/pubmed/27014622
http://dx.doi.org/10.3389/fonc.2016.00043
_version_ 1782421074525290496
author Gofrit, Ofer N.
Yutkin, Vladimir
Shapiro, Amos
Pizov, Galina
Zorn, Kevin C.
Hidas, Guy
Gielchinsky, Ilan
Duvdevani, Mordechai
Landau, Ezekiel H.
Pode, Dov
author_facet Gofrit, Ofer N.
Yutkin, Vladimir
Shapiro, Amos
Pizov, Galina
Zorn, Kevin C.
Hidas, Guy
Gielchinsky, Ilan
Duvdevani, Mordechai
Landau, Ezekiel H.
Pode, Dov
author_sort Gofrit, Ofer N.
collection PubMed
description BACKGROUND: High-grade urothelial carcinomas (UCs) often show foci of variant differentiation. There is limited information in the literature about the response of these variant urothelial tumors to immunotherapy with bacillus Calmette–Guerin (BCG). We compared the response, to treatment with BCG, of UC containing glandular, squamous, nested, and micropapillary types of differentiation to response of conventional non-muscle invasive high-grade UC. METHODS: A total of 100 patients were diagnosed with variant histology urothelial cancer between June 1995 and December 2013. Forty-one patients with Ta or T1, confirmed by second look biopsies, received immunotherapy with BCG. Fourteen patients in this group were diagnosed with micropapillary differentiation, 13 patients with squamous differentiation, 9 patients with glandular differentiation, and 7 patients with nested variants. The control group included 140 patients with conventional high-grade UC. Both groups have been treated and followed similarly. FINDINGS: Patients with variant tumors had similar clinical features to patients with conventional disease, including age, male to female ratio, stage, the presence of Tis, and median follow-up. Patients with variant tumors had a significantly worse prognosis compared to patients with conventional high-grade UC, including 5-year recurrence-free survival (63.5 Vs. 71.5%, p = 0.05), 5-year progression (≥T2)-free survival (60 Vs. 82.5%, p = 0.002), 5-year disease-specific survival (73 Vs. 92.5%, p = 0.0004), and overall survival (66 Vs. 89.5%, 0.05). INTERPRETATION: A patient with variant bladder cancer treated with intravesical immunotherapy has a 27% chance of dying from this disease within 5 years compared to 7.5% chance for a patient with conventional high-grade UC.
format Online
Article
Text
id pubmed-4791377
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-47913772016-03-24 The Response of Variant Histology Bladder Cancer to Intravesical Immunotherapy Compared to Conventional Cancer Gofrit, Ofer N. Yutkin, Vladimir Shapiro, Amos Pizov, Galina Zorn, Kevin C. Hidas, Guy Gielchinsky, Ilan Duvdevani, Mordechai Landau, Ezekiel H. Pode, Dov Front Oncol Oncology BACKGROUND: High-grade urothelial carcinomas (UCs) often show foci of variant differentiation. There is limited information in the literature about the response of these variant urothelial tumors to immunotherapy with bacillus Calmette–Guerin (BCG). We compared the response, to treatment with BCG, of UC containing glandular, squamous, nested, and micropapillary types of differentiation to response of conventional non-muscle invasive high-grade UC. METHODS: A total of 100 patients were diagnosed with variant histology urothelial cancer between June 1995 and December 2013. Forty-one patients with Ta or T1, confirmed by second look biopsies, received immunotherapy with BCG. Fourteen patients in this group were diagnosed with micropapillary differentiation, 13 patients with squamous differentiation, 9 patients with glandular differentiation, and 7 patients with nested variants. The control group included 140 patients with conventional high-grade UC. Both groups have been treated and followed similarly. FINDINGS: Patients with variant tumors had similar clinical features to patients with conventional disease, including age, male to female ratio, stage, the presence of Tis, and median follow-up. Patients with variant tumors had a significantly worse prognosis compared to patients with conventional high-grade UC, including 5-year recurrence-free survival (63.5 Vs. 71.5%, p = 0.05), 5-year progression (≥T2)-free survival (60 Vs. 82.5%, p = 0.002), 5-year disease-specific survival (73 Vs. 92.5%, p = 0.0004), and overall survival (66 Vs. 89.5%, 0.05). INTERPRETATION: A patient with variant bladder cancer treated with intravesical immunotherapy has a 27% chance of dying from this disease within 5 years compared to 7.5% chance for a patient with conventional high-grade UC. Frontiers Media S.A. 2016-03-15 /pmc/articles/PMC4791377/ /pubmed/27014622 http://dx.doi.org/10.3389/fonc.2016.00043 Text en Copyright © 2016 Gofrit, Yutkin, Shapiro, Pizov, Zorn, Hidas, Gielchinsky, Duvdevani, Landau and Pode. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Gofrit, Ofer N.
Yutkin, Vladimir
Shapiro, Amos
Pizov, Galina
Zorn, Kevin C.
Hidas, Guy
Gielchinsky, Ilan
Duvdevani, Mordechai
Landau, Ezekiel H.
Pode, Dov
The Response of Variant Histology Bladder Cancer to Intravesical Immunotherapy Compared to Conventional Cancer
title The Response of Variant Histology Bladder Cancer to Intravesical Immunotherapy Compared to Conventional Cancer
title_full The Response of Variant Histology Bladder Cancer to Intravesical Immunotherapy Compared to Conventional Cancer
title_fullStr The Response of Variant Histology Bladder Cancer to Intravesical Immunotherapy Compared to Conventional Cancer
title_full_unstemmed The Response of Variant Histology Bladder Cancer to Intravesical Immunotherapy Compared to Conventional Cancer
title_short The Response of Variant Histology Bladder Cancer to Intravesical Immunotherapy Compared to Conventional Cancer
title_sort response of variant histology bladder cancer to intravesical immunotherapy compared to conventional cancer
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4791377/
https://www.ncbi.nlm.nih.gov/pubmed/27014622
http://dx.doi.org/10.3389/fonc.2016.00043
work_keys_str_mv AT gofritofern theresponseofvarianthistologybladdercancertointravesicalimmunotherapycomparedtoconventionalcancer
AT yutkinvladimir theresponseofvarianthistologybladdercancertointravesicalimmunotherapycomparedtoconventionalcancer
AT shapiroamos theresponseofvarianthistologybladdercancertointravesicalimmunotherapycomparedtoconventionalcancer
AT pizovgalina theresponseofvarianthistologybladdercancertointravesicalimmunotherapycomparedtoconventionalcancer
AT zornkevinc theresponseofvarianthistologybladdercancertointravesicalimmunotherapycomparedtoconventionalcancer
AT hidasguy theresponseofvarianthistologybladdercancertointravesicalimmunotherapycomparedtoconventionalcancer
AT gielchinskyilan theresponseofvarianthistologybladdercancertointravesicalimmunotherapycomparedtoconventionalcancer
AT duvdevanimordechai theresponseofvarianthistologybladdercancertointravesicalimmunotherapycomparedtoconventionalcancer
AT landauezekielh theresponseofvarianthistologybladdercancertointravesicalimmunotherapycomparedtoconventionalcancer
AT podedov theresponseofvarianthistologybladdercancertointravesicalimmunotherapycomparedtoconventionalcancer
AT gofritofern responseofvarianthistologybladdercancertointravesicalimmunotherapycomparedtoconventionalcancer
AT yutkinvladimir responseofvarianthistologybladdercancertointravesicalimmunotherapycomparedtoconventionalcancer
AT shapiroamos responseofvarianthistologybladdercancertointravesicalimmunotherapycomparedtoconventionalcancer
AT pizovgalina responseofvarianthistologybladdercancertointravesicalimmunotherapycomparedtoconventionalcancer
AT zornkevinc responseofvarianthistologybladdercancertointravesicalimmunotherapycomparedtoconventionalcancer
AT hidasguy responseofvarianthistologybladdercancertointravesicalimmunotherapycomparedtoconventionalcancer
AT gielchinskyilan responseofvarianthistologybladdercancertointravesicalimmunotherapycomparedtoconventionalcancer
AT duvdevanimordechai responseofvarianthistologybladdercancertointravesicalimmunotherapycomparedtoconventionalcancer
AT landauezekielh responseofvarianthistologybladdercancertointravesicalimmunotherapycomparedtoconventionalcancer
AT podedov responseofvarianthistologybladdercancertointravesicalimmunotherapycomparedtoconventionalcancer